ZyVersa Therapeutics annual current ratio
2021
2022
2023
2024
2025
ZyVersa Therapeutics Current Ratio Growth & History (ZVSA)
ZyVersa Therapeutics's current ratio was 0.04 for fiscal 2025.
View full ZyVersa Therapeutics company overviewZyVersa Therapeutics annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.04 | −0.12 | −76.39% |
| 2024 | 2024-12-31 | 0.15 | −0.18 | −53.55% |
| 2023 | 2023-12-31 | 0.33 | −0.45 | −57.67% |
| 2022 · Dec 31 | 2022-12-31 | 0.78 | −3.49 | −81.77% |
| 2021 | 2021-12-31 | 4.26 | — | — |
ZyVersa Therapeutics quarterly current ratio
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q1 2026 | 2026-03-31 | 0.05 | −0.13 | −71.60% |
| Q4 2025 | 2025-12-31 | 0.04 | −0.12 | −76.39% |
| Q3 2025 | 2025-09-30 | 0.08 | 0.04 | +130.55% |
| Q2 2025 | 2025-06-30 | 0.04 | −0.02 | −32.57% |
| Q1 2025 | 2025-03-31 | 0.18 | −0.13 | −41.91% |
| Q4 2024 | 2024-12-31 | 0.15 | −0.18 | −53.55% |
| Q3 2024 | 2024-09-30 | 0.03 | −0.14 | −80.25% |
| Q2 2024 | 2024-06-30 | 0.06 | −0.04 | −39.69% |
| Q1 2024 | 2024-03-31 | 0.30 | −0.03 | −8.41% |
| Q4 2023 | 2023-12-31 | 0.33 | −0.45 | −57.67% |
| Q3 2023 | 2023-09-30 | 0.17 | −0.10 | −36.53% |
| Q2 2023 | 2023-06-30 | 0.11 | −0.62 | −85.44% |
| Q1 2023 | 2023-03-31 | 0.33 | −0.94 | −74.06% |
| Q4 2022 | 2022-12-31 | 0.78 | −3.49 | −81.77% |
| Q3 2022 | 2022-09-30 | 0.27 | — | — |
| Q2 2022 | 2022-06-30 | 0.73 | — | — |
| Q1 2022 | 2022-03-31 | 1.27 | — | — |
| Q4 2021 | 2021-12-31 | 4.26 | — | — |
ZyVersa Therapeutics current ratio trends
Between the periods ended 2021-12-31 and 2025-12-31, ZyVersa Therapeutics's current ratio decreased from 4.26 to 0.04, a change of −4.23. The latest reported quarter, Q1 2026, shows 0.05.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review ZyVersa Therapeutics source filings ↗